Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.
Giorgio Mustacchi(University of Trieste), Laura Iezzi(Ospedale SS. Annunziata), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Filippo Montemurro(Roche (Switzerland)), Monica Giordano(Ospedale Sant'Anna), P. Pronzato(Accademia Nazionale dei Lincei), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Alessandra Beano(Presidio Ospedaliero), Lorenzo Livi(European Society for Sexual Medicine), Laura Biganzoli(Hospital of Prato), Anna Turletti(Ospedale Martini), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Emanuela Romagnoli(Medica (Italy)), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Andrea Michelotti(University of Pisa)
Cited by 0
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k